Androgen deficiency, palliative care
Conditions
Brief summary
Best improvement over time in independence using the ADL independence scale in terms of personal hygiene, dressing, going to the toilet, locomotion, continence and eating, Best improvement over time in symptoms of pain, fatigue, sadness, anxiety, drowsiness, appetite, sense of well-being, shortness of breath, bowel movements and strength using the Edmonton Symptom Assessment Scale
Detailed description
The average of ADL and Edmonton Symptom Assessment Scale during treatment after baseline. The ADL and Edmonton System Assessment Scale at each time point during treatment, especially at D15., Improvement of quality of life of subjects from the point of view of a proxy using the EQ-5D-3L questionnaire.
Interventions
DRUGSustanon 250
DRUGsolution injectable
Sponsors
Institut Jules Bordet
Eligibility
Sex/Gender
Male
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best improvement over time in independence using the ADL independence scale in terms of personal hygiene, dressing, going to the toilet, locomotion, continence and eating, Best improvement over time in symptoms of pain, fatigue, sadness, anxiety, drowsiness, appetite, sense of well-being, shortness of breath, bowel movements and strength using the Edmonton Symptom Assessment Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| The average of ADL and Edmonton Symptom Assessment Scale during treatment after baseline. The ADL and Edmonton System Assessment Scale at each time point during treatment, especially at D15., Improvement of quality of life of subjects from the point of view of a proxy using the EQ-5D-3L questionnaire. | — |
Countries
Belgium
Outcome results
None listed